EUVIMEDEUVIMED entdecken
Open Access · CC BY 2.0

Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model

Bellina A S Mushala, Michael W Stoner, Maryam Sharifi-Sanjani, Janet R Manning, Paramesha Bugga, Nisha Bhattarai, Brenda McMahon, Amber Vandevender, Steven J Mullet, Brett A Kaufman, Sruti S Shiva, Cheng Zhang und 5 weitere

Clinical Science · 15.07.2026 · 140 (7) · 1399-1414

DOI: 10.1042/cs20261501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 22.06.2026. Verfasst von Bellina A S Mushala und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A. Hauptthemen laut MEDLINE: Heart Failure, Ventricular Remodeling, Intercellular Signaling Peptides and Proteins, Stroke Volume. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: NHLBI NIH HHS, HHS | NIH | NIH Office of the Director (OD), NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is a heterogenous metabolic disease, which in the heart presents as left ventricle diastolic dysfunction, ventricular stiffness, and myocardial structural remodeling. Deleterious changes in cardiac metabolism are central to HFpEF pathophysiology, and proposed treatments for the disease have focused on repairing these defects. In the present study, we used a preclinical mouse model that recapitulates cardiometabolic HFpEF to elucidate the molecular mechanisms driving cardiac dysfunction and tested whether recombinant adropin (Adr.) (a liver- and brain-derived endogenous peptide hormone) could reverse observed defects. We show that long-term treatment with Adr. reversed multiple markers of HFpEF-related cardiac dysfunction (including fibrosis, diastolic dysfunction, and cardiomyocyte hypertrophy). Using untargeted metabolomics, we found that Adr. treatment reduced hexosamine biosynthesis pathway activity, leading to a reduction in the O-GlcNAcylation of the cardiac fatty acid oxidation enzyme long-chain acyl-CoA dehydrogenase (LCAD). Reducing LCAD O-GlcNAcylation increased LCAD activity in vitro and reduced the accumulation of long-chain acylcarnitines in HFpEF mouse hearts in vivo. Our results suggest that Adr. may restore cardiac metabolic function in HFpEF and that targeting this pathway may be a novel therapeutic avenue for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureVentricular RemodelingIntercellular Signaling Peptides and ProteinsStroke VolumeBlood ProteinsAnimalsMaleDisease Models, AnimalMice, Inbred C57BLMiceAcyl-CoA Dehydrogenase, Long-ChainMyocardiumHexosaminesCarnitineMyocytes, Cardiac

Stichwörter der Autor:innen

fatty acid oxidationheart failuremitochondria

Substanzen

Enho protein, mouseIntercellular Signaling Peptides and ProteinsAcyl-CoA Dehydrogenase, Long-ChainBlood ProteinsHexosaminesCarnitine

Autor:innen und Institutionen

  • Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
  • Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
  • Division of Cardiology, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
  • Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
  • Health Sciences Mass Spectrometry Core, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
  • Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.

ORCID-Profile: Iain Scott

Förderung

  • NHLBI NIH HHS
  • HHS | NIH | NIH Office of the Director (OD)
  • NCI NIH HHS
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • NIH HHS
  • NIDDK NIH HHS
  • American Heart Association (AHA)

Zitieren

APA

Mushala, B. A. S., Stoner, M. W., Sharifi-Sanjani, M., Manning, J. R., Bugga, P., Bhattarai, N., McMahon, B., Vandevender, A., Mullet, S. J., Kaufman, B. A., Shiva, S. S., Zhang, C., Goetzman, E. S., Chan, S. Y., Gelhaus, S. L., Jurczak, M. J., & Scott, I. (2026). Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model. Clinical Science, 140(7), 1399-1414. https://doi.org/10.1042/cs20261501

Vancouver

Mushala BAS, Stoner MW, Sharifi-Sanjani M, Manning JR, Bugga P, Bhattarai N, et al. Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model. Clinical Science. 2026;140(7):1399-1414. doi:10.1042/cs20261501

BibTeX
@article{Mushala2026,
  author = {Mushala, Bellina A S and Stoner, Michael W and Sharifi-Sanjani, Maryam and Manning, Janet R and Bugga, Paramesha and Bhattarai, Nisha and McMahon, Brenda and Vandevender, Amber and Mullet, Steven J and Kaufman, Brett A and Shiva, Sruti S and Zhang, Cheng and Goetzman, Eric S and Chan, Stephen Y and Gelhaus, Stacy L and Jurczak, Michael J and Scott, Iain},
  title = {Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model},
  journal = {Clinical Science},
  year = {2026},
  volume = {140},
  number = {7},
  pages = {1399--1414},
  doi = {10.1042/cs20261501}
}
Kostenlos starten →